Sep 17, 2021 04:11 PM (GMT+8) · EqualOcean
Financial Associated Press, September 17 - Nanjing Pharmaceutical announced that the fixed increase project was approved by Xingong group: it agreed to the company's non-public offering plan, the pricing principle and method of issuing shares were implemented in accordance with the current regulations, and the raised funds were used to supplement working capital and repay interest bearing liabilities. Within the validity period approved by the CSRC, the company issued no more than 251 million shares to Xingong group (including this amount). Xingong group subscribes all the shares of the company's non-public offering in cash.

This text is a result of machine translation.